首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >Promising potency of retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment
【2h】

Promising potency of retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment

机译:维甲酸-聚乙二醇-硫醇金纳米颗粒结合物在宫颈癌治疗中的潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We investigated the effect of synthesized retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates on cervical carcinoma cells. Cervical cancer is the major cause of deaths for the women of reproductive age in the developing countries. Compared to retinoic acid, the nanoparticle conjugates exhibited better activity against cervical carcinoma. Selective delivery of gold nanoparticle conjugates to estrogen receptor positive cervical cancer cells with 6-fold enhanced drug potency was observed. Transfer of gold nanoparticles was found to be dominated by estrogen ligand and receptor. It appeared that retinoic acid nanoparticle conjugates were selectively taken and retained by the estrogen receptor alpha present in the plasma membrane. Thus IC50 values for RA-PEG-SH were significantly improvedon nanoparticle ligation. Cells on treatment with RA-PEG-SH-AuNPsshowed growth inhibition at 12 and 24 h after incubation. The IC50 for RA in RA-PEG-SH-AuNPs after 12 and 24 h were 3 and 1 μM, respectively. Thus, the use of RA nanoparticle conjugates can be a better strategy for cervical carcinoma treatment.
机译:我们调查了合成的视黄酸-聚(乙二醇)-硫醇金纳米粒子共轭物对宫颈癌细胞的影响。宫颈癌是发展中国家育龄妇女死亡的主要原因。与视黄酸相比,纳米粒子结合物表现出更好的抗宫颈癌活性。观察到金纳米颗粒结合物选择性递送至雌激素受体阳性子宫颈癌细胞,药物效力提高了6倍。发现金纳米颗粒的转移受雌激素配体和受体支配。似乎视黄酸纳米颗粒结合物被质膜中存在的雌激素受体α选择性地吸收和保留。因此,RA-PEG-SH的IC 50值在纳米颗粒连接中显着提高。用RA-PEG-SH-AuNPs处理的细胞在孵育后12和24 h表现出生长抑制作用。 12和24小时后,RA-PEG-SH-AuNPs中RA的IC50分别为3和1μM。因此,使用RA纳米粒子结合物可以是治疗宫颈癌的更好策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号